Researchers at the Telethon Institute of Genetics and Medicine (TIGEM), Pozzuoli, Italy, has reported the results of 5,054 gene transcripts analysed from 218 IRD (inherited… Read More »A novel overview of the human retinal transcriptome may contribute missing heritability in IRD patients
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the April 16th, 2023 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA… Read More »April 16th, 2023 “EURETINA-Brief”© Issue No. 269
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), a clinical stage company based in Lexington, Massachusetts, has reported the completion of the enrollment of a Phase 2 clinical… Read More »Aldeyra Therapeutics Inc., (NASDAQ: ALDX) reports the completion of enrollment in a Phase 2 study for methotrexate to treat Pro23His retinitis pigmentosa (RP)
Researchers at the Ophthalmology Unit, Fondazione Policlinico Universitario Agostino in Rome, has reported that pathogenic variants in the eyes shut homolog (EYS) gene are estimated… Read More »Retinitis pigmentosa arising from EYS gene mutations have reported novel insights from combined measurements for a RP stage score system (RP-SSS)
Researchers at McMaster University, Hamilton, Ontario reported that a systematic review and meta-analysis of global prevalence of diabetic retinopathy (DR), in paediatric type 2 diabetes… Read More »Global priority that needs increased attention of diabetic retinopathy in children with Type 2 diabetes
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the March 28th, 2023 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA… Read More »March 28th, 2023 “EURETINA-Brief”© Issue No. 268
Opus Genetics Inc., a private ocular gene therapy company based in Raleigh, North Carolina, has announced the acquisition of rights to two preclinical-stage AAV-based gene… Read More »Opus Genetics Inc., has announced the acquisition of rights to two preclinical-stage for inherited retinal diseases (IRDs) from Iveric Bio (NASDAQ: ISEE)
Researchers, clinicians and patients & families are to support a workshop in La Jolla, San Diego (March 29th-31st) for those focused on finding treatments on… Read More »A Peripherin 2 (Prph2) retinal disease workshop is scheduled with international researchers, clinicians and patients, supported by Foundation Fighting Blindness
Researchers at the Institute of Mathematics, Kassel University and the Department of Ophthalmology, Heidelberg University, have reported a novel in silico model and algorithm for… Read More »A novel in silico model and algorithm for refining therapeutic treatment of retinal disease
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the March 8th, 2023 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA… Read More »March 8th, 2023 “EURETINA-Brief”© Issue No. 267
